NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Tuesday reported a loss of $86.6 million in its second quarter.
The New York-based company said it had a loss of 92 cents per share.
The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 79 cents per share.
The biopharmaceutical company posted revenue of $55.6 million in the period, topping Street forecasts. Four analysts surveyed by Zacks expected $49.2 million.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ITCI at https://www.zacks.com/ap/ITCI
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News